📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Krebs Biochemicals Q3 Loss Narrows to ₹3.13 Cr; Revenue Declines 36% YoY
Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.
Key Highlights
Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.
Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.
Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.
The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.
Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.
💼 Action for Investors
Investors should remain highly cautious as the company faces severe financial distress with negative net worth and ongoing regulatory issues at its Vizag plant. The significant drop in revenue and high debt levels make this a high-risk situation despite the narrowing of quarterly losses.